Please assess the completion status of the following clinical trial:

Trial Title: PRe-Exposure Prophylaxis Acceptability & Readiness Assessments for Toronto gaY, Bisexual and Other Men Who Have Sex With Men-5

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Self-identified man who has sex with men~* Age 18 years or older~* Able to communicate in both written and oral english~* HIRI-MSM score greater than or equal to 10~* At least one self-reported unprotected receptive anal sex act over the preceding 6 months~* Creatinine clearance greater than or equal to 60mL/min by Modified Diet in Renal Disease (MDRD) formula~* HIV un-infected at screening using standard ELISA and Western Blot testing~Exclusion Criteria:~* Clinical signs or symptoms suggestive of an HIV seroconversion illness within the last 3 months in the opinion of the investigator~* Use of pre- or post-exposure prophylaxis within the last 3 months~* Use of concomitant nephrotoxic drugs~* Use of concomitant immune modulatory drugs~* Hepatitis B surface antigen positivity~* Any condition or concomitant medication portending an increased risk of osteoporosis~* Enrollment in any other HIV prevention program or trial

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Tenofovir/emtricitabine (Type: EXPERIMENTAL): MSM receiving once daily TDF/FTC-based (Truvada®) pre-exposure prophylaxis

Based on this trial design, predict the completion outcome and termination type (if applicable).